Gil-Gil, MiguelAlba, EmilioGavila, Joaquinde la Haba-Rodriguez, JuanCiruelos, EvaTolosa, PabloCandini, DanieleLlombart-Cussac, Antonio2023-02-092023-02-092021-05-21Gil-Gil M, Alba E, Gavilá J, de la Haba-Rodríguez J, Ciruelos E, Tolosa P, et al. The role of CDK4/6 inhibitors in early breast cancer. Breast. 2021 Aug;58:160-169http://hdl.handle.net/10668/17956The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.enAttribution-Noncommercial-Noderivs 4.0 Internationalhttps://creativecommons.org/licenses/by-nc-nd/4.0/AbemaciclibAdjuvant therapyCyclin-dependent kinase 4/6 inhibitorsEarly breast cancerPalbociclibBreast neoplasmsCyclin-dependent kinase 4Cyclin-dependent kinase 6FemaleHumansProtein kinase inhibitorsResearch article34087775open accessInhibidores de proteínas quinasasNeoplasias de la mamaQuinasa 4 dependiente de la ciclinaQuinasa 6 dependiente de la ciclina10.1016/j.breast.2021.05.0081532-3080PMC8184648http://www.thebreastonline.com/article/S0960977621003805/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184648/pdf